摘要
偏头痛是最常见的失能性原发性头痛,疾病负担沉重。近年来,国际上开展了诸多偏头痛预防性新药的临床试验,显著推动了偏头痛治疗的快速进展。我国偏头痛治疗的临床试验尚处于起步阶段,为促进和规范我国偏头痛预防性治疗的临床对照试验,提供临床试验设计、实施和评价方面的方法学指导,中华医学会神经病学分会头痛协作组借鉴国际头痛协会偏头痛临床研究的新进展,并结合我国偏头痛临床研究实际情况,制定了中国成人偏头痛预防性治疗药物临床对照试验专家共识。
Migraine is the most common disabling primary headache with a significant socioeconomic burden.At present,some emerging drugs for migraine preventive treatment are under investigation internationally,which significantly promote the progress of migraine treatment.However,only few of this trial for migraine treatment are explored in China.In order to promote and standardize controlled clinical trials of migraine preventive therapy in China,and to provide methodological guidance for the design,implementation and evaluation of clinical trials,the Headache Collaborators of Chinese Society of Neurology formulated this consensus.
作者
中华医学会神经病学分会头痛协作组
王永刚
刘恺鸣
Headache Collaborators of Chinese Society of Neurology;Wang Yonggang;Liu Kaiming(不详;Bejing Tiantan Hospital,Capital Medical University,Beiing 100070,China;the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China)
出处
《中华内科杂志》
CAS
CSCD
北大核心
2023年第5期494-506,共13页
Chinese Journal of Internal Medicine
关键词
偏头痛
治疗
预防医学
临床试验
专家共识
Migraine
Treatment
Preventive medicine
Clinical trial
Expert consensus
